|Bid||201.13 x 900|
|Ask||201.14 x 800|
|Day's range||199.16 - 202.40|
|52-week range||185.33 - 285.57|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||19.10|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Today, let's turn our attention to gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP). The stock market performance of a clinical-stage biotech like CRISPR Therapeutics is largely tied to the perceived successes (or potential failures) of its pipeline candidates. The company's approach centers on gene editing, which refers to a set of techniques that allow scientists to modify an organism's DNA.
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.
Many biotech companies have been formed hoping to be first to market with CRISPR gene-editing therapies. CRISPR Therapeutics (NASDAQ: CRSP) and its development partner Vertex Pharmaceuticals (NASDAQ: VRTX) are leading the way with the CTX001 therapy for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). On June 11, CRISPR Therapeutics and Vertex held a joint press conference highlighting CTX001 results, which showed that patients in a 22-person phase 1/2 clinical trial are having a "consistent and sustained response to treatment."